In vitro responsiveness of human-drug-resistant tissue to antiepileptic drugs:
Date: 8.6.2006
Pharmacoresistance in epileptic patients may be ascribed to at least two, not mutually exclusive, mechanisms: a pharmacokinetic mechanism and a decreased sensitivity or availability of targets to antiepileptic drugs (AEDs; i.e., carbamazepine and phenytoin (CBZ, PHT)).
Brain:plasma drug concentration ratios were determined intraoperatively during lobectomies performed to alleviate drug-resistant seizures. The brain:plasma ratio of CBZ was 1.48 when therapeutic serum levels (15–34 μM) were achieved. When concentrations of CBZ found in multiple-drug-resistant brain were directly applied to human cortical slices from drug-resistant patients made hyperexcitable and hypersynchronous by Mg2+-free media, bursting frequency was not significantly affected and overall excitability was reduced by 40%. Similar results were obtained for PHT.
At higher AED concentrations (60–200 μM), a dose-dependent decrease of bursting frequency and amplitude was observed. Slices from drug-resistant epileptic patients made hypersynchronous/hyperexcitable by elevated potassium or inhibition of GABA-A receptors behaved similarly. Of note is the response of slices from human multiple-drug-resistant brain, which was greater than in rodent cortex from naive animals. Taken together, our results support the hypothesis that multiple drug resistance to AEDs involves cerebrovascular changes that impede the achievement of appropriate drug levels in the central nervous system.
"Source":[ http://www.sciencedirect.com/science?_ob=ArticleURL&_aset=V-WA-A-W-AUUU-MsSAYWW-UUW-U-AACAUUEYYW-AAVYCEUZYW-YYEVCUUYB-WVBZ-U&_rdoc=30&_fmt=full&_udi=B6SYR-4JT3S6M-1&_coverDate=05%2F01%2F2006&_cdi=4841&_orig=search&_st=13&_sort=d&view=c&_acct=C000045159&_version=1&_urlVersion=0&_userid=835458&md5=f0d574c703f47042f8b075cebca39acd]
Related articles
New drug shows promise for epilepsy - German researchers say a new drug shows promise for treating epileptic seizures and may prove beneficial for bi-polar disorder and neuropathic pain (8.4.2007)
